Roots-Analysis-Logo.png
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis
28 oct. 2021 07h30 HE | Roots Analysis
London, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare...
Full Latin without Latin logo.png
Innovative drug launched for rare, isolating, “light intolerance” disorder
16 avr. 2020 02h53 HE | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP
06 juil. 2016 08h00 HE | Clinuvel Pharmaceuticals Limited
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...